EXAS Quote, Financials, Valuation and Earnings

Danaher has a net margin of -121.19% compared to Exact Sciences's net margin of 16.61%. Exact Sciences's return on equity of -34.11% beat Danaher's return on equity of 7.57%.

Exact Sciences has a consensus price target of $68.47, signalling upside risk potential of 69.86%. On the other hand Danaher has an analysts' consensus of $261.35 which suggests that it could grow by 49.65%. Given that Exact Sciences has higher upside potential than Danaher, analysts believe Exact Sciences is more attractive than Danaher.

Exact Sciences has a beta of 1.136, which suggesting that the stock is 13.608% more volatile than S&P 500. In comparison Danaher has a beta of 0.866, suggesting its less volatile than the S&P 500 by 13.413%.

Exact Sciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Danaher offers a yield of 0.65% to investors and pays a quarterly dividend of $0.32 per share. Exact Sciences pays -- of its earnings as a dividend. Danaher pays out 19.7% of its earnings as a dividend. Danaher's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Exact Sciences quarterly revenues are $713.4M, which are smaller than Danaher quarterly revenues of $6.5B. Exact Sciences's net income of -$864.6M is lower than Danaher's net income of $1.1B. Notably, Exact Sciences's price-to-earnings ratio is -- while Danaher's PE ratio is 33.08x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Exact Sciences is 2.69x versus 5.39x for Danaher. Usually stocks with elevated PS ratios are considered overvalued.

Guardant Health has a net margin of -121.19% compared to Exact Sciences's net margin of -55%. Exact Sciences's return on equity of -34.11% beat Guardant Health's return on equity of -8518.58%.

Exact Sciences has a consensus price target of $68.47, signalling upside risk potential of 69.86%. On the other hand Guardant Health has an analysts' consensus of $56.85 which suggests that it could grow by 42.8%. Given that Exact Sciences has higher upside potential than Guardant Health, analysts believe Exact Sciences is more attractive than Guardant Health.

Exact Sciences has a beta of 1.136, which suggesting that the stock is 13.608% more volatile than S&P 500. In comparison Guardant Health has a beta of 1.448, suggesting its more volatile than the S&P 500 by 44.847%.

Exact Sciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Guardant Health offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Exact Sciences pays -- of its earnings as a dividend. Guardant Health pays out -- of its earnings as a dividend.

Exact Sciences quarterly revenues are $713.4M, which are larger than Guardant Health quarterly revenues of $201.8M. Exact Sciences's net income of -$864.6M is lower than Guardant Health's net income of -$111M. Notably, Exact Sciences's price-to-earnings ratio is -- while Guardant Health's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Exact Sciences is 2.69x versus 6.61x for Guardant Health. Usually stocks with elevated PS ratios are considered overvalued.

Illumina has a net margin of -121.19% compared to Exact Sciences's net margin of 16.94%. Exact Sciences's return on equity of -34.11% beat Illumina's return on equity of -35.09%.

Exact Sciences has a consensus price target of $68.47, signalling upside risk potential of 69.86%. On the other hand Illumina has an analysts' consensus of $126.80 which suggests that it could grow by 80.38%. Given that Illumina has higher upside potential than Exact Sciences, analysts believe Illumina is more attractive than Exact Sciences.

Exact Sciences has a beta of 1.136, which suggesting that the stock is 13.608% more volatile than S&P 500. In comparison Illumina has a beta of 1.376, suggesting its more volatile than the S&P 500 by 37.551%.

Exact Sciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Illumina offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Exact Sciences pays -- of its earnings as a dividend. Illumina pays out -- of its earnings as a dividend.

Exact Sciences quarterly revenues are $713.4M, which are smaller than Illumina quarterly revenues of $1.1B. Exact Sciences's net income of -$864.6M is lower than Illumina's net income of $187M. Notably, Exact Sciences's price-to-earnings ratio is -- while Illumina's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Exact Sciences is 2.69x versus 2.56x for Illumina. Usually stocks with elevated PS ratios are considered overvalued.

Natera has a net margin of -121.19% compared to Exact Sciences's net margin of -11.3%. Exact Sciences's return on equity of -34.11% beat Natera's return on equity of -21.3%.

Exact Sciences has a consensus price target of $68.47, signalling upside risk potential of 69.86%. On the other hand Natera has an analysts' consensus of $189.62 which suggests that it could grow by 43.41%. Given that Exact Sciences has higher upside potential than Natera, analysts believe Exact Sciences is more attractive than Natera.

Exact Sciences has a beta of 1.136, which suggesting that the stock is 13.608% more volatile than S&P 500. In comparison Natera has a beta of 1.804, suggesting its more volatile than the S&P 500 by 80.37%.

Exact Sciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Natera offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Exact Sciences pays -- of its earnings as a dividend. Natera pays out -- of its earnings as a dividend.

Exact Sciences quarterly revenues are $713.4M, which are larger than Natera quarterly revenues of $476.1M. Exact Sciences's net income of -$864.6M is lower than Natera's net income of -$53.8M. Notably, Exact Sciences's price-to-earnings ratio is -- while Natera's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Exact Sciences is 2.69x versus 9.72x for Natera. Usually stocks with elevated PS ratios are considered overvalued.